PAX2 and PAX8 Reliably Distinguishes Ovarian Serous Tumors From Mucinous Tumors

Abstract

Ovarian cancer is the leading cause of cancer-related death in gynecologic malignancies and consists of different histologic types. Histopathologic examination and accurate subtype diagnosis has become increasingly important in guiding patient management and, as such, is the most important currently available ovarian carcinoma "biomarker." In this study, we examined the expression of PAX2 and PAX8 by immunohistochemistry in 58 cases of ovarian serous tumors and 68 cases of ovarian mucinous tumors. The results demonstrated that PAX2 and PAX8 were detected in 100% (30/30) and 77% (23/30) of serous cystadenomas, 100% (16/16) and 94% (15/16) of borderline serous cystadenomas, and 100% (12/12) and 83% (10/12) of serous carcinomas, respectively. However, PAX2 and PAX8 were detected in only 0% (0/29) and 0% (0/29) of mucinous cystadenoma, 4% (1/24) and 4% (1/24) of borderline mucinous cystadenoma, and 0% (0/15) and 7% (1/15) of mucinous carcinoma, respectively. Further, there is a linear correlation between PAX2 and PAX8 (R=0.745; P<0.0001). Overall, our data indicated that PAX2 correlated with PAX8, and these 2 proteins differentially expressed in ovarian serous tumors and ovarian mucinous tumors. Thus, PAX2 and PAX8 are useful biomarker in the differential diagnosis of ovarian serous and mucinous tumors.

Pharmacological Inhibition of p38 MAPK by SB203580 Increases Resistance to Carboplatin in A2780cp Cells and Promotes Growth in Primary Ovarian Cancer Cells

“…These cells display different morphology, indicating the heterogeneity in cell morphology among the samples (Supplementary Figure S3). We confirmed that the ascites-derived cells express paired-box gene 8 (PAX8, a marker for serous ovarian cancer) as determined by immunocytochemistry and Western blotting (Supplementary Figures S4 and S5) [29,30,31], as well as cytokeratins as determined by Western blotting using a pan-keratin antibody (Supplementary Figure S5) as we previously reported in EOC cell line SKOV3 and OVCA429 cells [32]. These data thus confirmed the EOC origin of the ascites-derived cells.…”

Paired box gene 2 is associated with estrogen receptor α in ovarian serous tumors: Potential theory basis for targeted therapy

“…Immunohistochemistry was performed to assess the expression of PAX2 and ERα in ovarian serous tumors and mucinous tumors. Our previous results revealed that PAX2 was expressed in 100% ovarian serous tumors (9). Other researchers revealed PAX2 expression in ≥60% serous carcinomas (10,11).…”

“…In our previous study, it was demonstrated that the expression of PAX2 was restricted to all 58 ovarian serous tumor types (Table I). By contrast, only one sample was positive in 68 mucinous tumors from the same patients (Table II) (9).…”

“…Patients who received no pre-operative chemoradiation treatment and had post-operative diagnosis as ovarian tumors were randomly selected for the present study. All specimens were the same as used in our previous study (9). It should be noted that one of ovarian mucinous tumors in our previous study was not included in the present study due to a lack of tissue.…”

Candidate genes and pathways downstream of PAX8 involved in ovarian high-grade serous carcinoma

“…In tumors, PAX8 is involved in the progression of follicular thyroid carcinomas [12] and it is overexpressed in the majority of gliomas, Wilms tumors and well-differentiated pancreatic neuroendocrine tumors [10, 13, 14]. In the scenario of ovarian cancer, PAX8 is the currently available most important marker [15] being a useful IHC target for the diagnosis of Mullerian tumors [16]. Despite PAX8 is normally expressed in Fallopian tube secretory cells, namely the cell of origin of HGSC, and is mainly considered a marker of tumor origin, we have recently reported its pivotal function in the tumorigenic phenotype of ovarian cancer cells.…”